Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
Gastroenterology and Hepatology from Bed to Bench,
,
26 January 2021
https://doi.org/10.22037/ghfbb.v14i1.1897
Abstract
Background
Neuroendocrine tumors of the gastrointestinal tract and pancreas include a range of rare and diverse neoplasms with unique tumor biology, natural history, and clinical management. Neuroendocrine tumors of the ampulla of Vater, are extremely uncommon cancers that account for only about 0.3%-1% of all gastrointestinal neuroendocrine tumors. Approximately 139 cases have been reported to date.
Materials and methods
In this paper, we describe two patients with low to intermediate grades of ampullary neuroendocrine tumors that underwent multiple courses of chemotherapy with Capecitabine (Xeloda®) and Temozolomide (Temodal®).
Results
Our two patients had a very dramatic response to this regimen.
Conclusion
According to our study, it seems that ampullary neuroendocrine tumors have behavior like pancreatic neuroendocrine tumors and confirmation of this finding needs further investigations in more patients.
- Neuroendocrine Tumors
- Vater's Ampulla
- Capecitabine
- Temozolomide
References
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29(7):934-43 [PMID: 21263089 DOI: 10.1200/JCO.2010.33.2056]
Ricci JL. Carcinoid of the ampulla of Vater. Local resection or pancreaticoduodenectomy. Cancer 1993; 71(3):686-90 [PMID: 8094317]
Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumors of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 2015; 5(5):e008248 [PMID: 25991462 DOI: 10.1136/bmjopen-2015-008248]
Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, Eickhoff J, Chen H, Loconte NK. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Theoncologist 2011; 16(6):835-43 [PMID: 21632454 DOI: 10.1634/theoncologist.2011-0031]
Seoung Ho Lee, Tae Hoon Lee, Si-Hyong Jang, Chi Young Choi, Won Myung Lee, Ji Hey Min, Hyun Deuk Cho, Sang-Heum Park. Ampullary neuroendocrine tumor diagnosed by endoscopic papillectomy in previously confirmed ampullary adenoma. World J Gastroenterol 2016; 22(13):3687-92 [PMID: 27053861 DOI: 10.3748/wjg.v22.i13.3687]
Jayant M, Punia R, Kaushik R, Sharma R, Sachdev A, Nadkarni NK, Attri A. Neuroendocrine tumors of the ampulla of vater: presentation, pathology and prognosis. JOP 2012; 13(3):263-7 [PMID: 22572129]
Mehmet Odabasi, Kamil Mehmet Yildiz, Eris Cengiz, Abuoglu Haci Hasan, Emre Gunay, Erkan Ozkan, Ali Aktekin, Bulent Kaya, Tolga Munip Ali Muftuoglu. Treatment of ampullary neuroendocrine tumor by endoscopic snare papillectomy. Am J Case Rep 2013; 14:439-43 [PMID: 24179583 DOI: 10.12659/AJCR.889601]
Hatzitheoklitos E, Büchler MW, Friess H, Poch B, Ebert M, Mohr W, Imaizumi T, Beger HG. Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer 1994; 73(6):1580-8 [PMID: 8156484]
Jaques Waisberg, George Joppert-Netto, Raquel Yumi Yonamine, Daniel Reis Waisberg, Maria Isete Fares Francoet. Neuroendocrine Tumor of the Ampulla of Vater: A Rare Neoplasm in an Atypical Site. Report of Three Cases and Review of the Literature. JOP 2016; 17(5):538-542 [ISSN 1590-8577]
Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Neuroendocrine tumors of the ampulla of Vater: biological behavior and surgical management. Arch Surg 2009; 144(6):527-31 [PMID: 19528385 DOI: 10.1001/archsurg.2009.80]
Andrew Ofosu, Michael Taccone, Laskhmi Potakamuri, Sanjay Jagannath. Ampullary Neuroendocrine Tumor: A Rare Cause of Recurrent Abdominal Pain. Crcm 2014; [DOI: 10.4236/crcm.2014.33034]
Mariko Tsukagoshi, Yasuo Hosouchi, Kenichiro Araki, Yasushi Mochida, Ryusuke Aihara, Ken Shirabe, Hiroyuki Kuwano. Neuroendocrine tumor of the ampulla of Vater with distant cystic lymph node metastasis: a case report. Surg Case Rep 2016; 2(1):73 [PMID: 27457078 DOI: 10.1186/s40792-016-0202-1]
Abbasi S, Kashashna A, Albaba H. Efficacy of capecitabine and Temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. Pancreas 2014; 43(8):1303-5 [PMID: 25036906 DOI: 10.1097/MPA.0000000000000174]
Mahjoub AR, O'Reilly EM. Emerging therapies for pancreas neuroendocrine cancers. Chin Clin Oncol 2013; 2(3):23 [PMID: 25841679 DOI: 10.3978/j.issn.2304-3865.2013.06.01]
Devata S, Kim EJ. Neoadjuvant chemotherapy with capecitabine and Temozolomide for unresectable pancreatic neuroendocrine tumor. Case Rep Oncol 2012; 5(3):622-6 [PMID: 23275776 DOI: 10.1159/000345369]
Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointest Cancer Res 2013; 6(4 Suppl 1):S10-2 [PMID: 24312683]
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and Temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117(2):268-75 [PMID: 20824724 DOI: 10.1002/cncr.25425]
Miljković MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 2012; 57(1):9-18 [PMID: 21938486 DOI: 10.1007/s10620-011-1854-0]
Yang K, Yun SP, Kim S, Shin N, Park DY, Seo HI. Clinicopathological features and surgical outcomes of neuroendocrine tumors of ampulla of Vater. BMC Gastroenterol 2017; 17(1):70 [PMID: 28569146 DOI: 10.1186/s12876-017-0630-9]
- Abstract Viewed: 0 times
